Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

entecavir

- PMLiVE

Lilly taps Strides Arcolab for cancer generics

Aims to expand its presence in emerging pharmaceutical markets

- PMLiVE

BMS cuts Orencia price to win NICE over

Draft guidance now backs drug for earlier stage of rheumatoid arthritis treatment

Bristol-Myers Squibb (BMS) building

BMS ends development of Alzheimer’s candidate avagacestat

Amyloid-targeting candidate fails to make it to phase III trials

- PMLiVE

Teva plans revamp as 2013 revenues expected to fall short

Expects increased competition for biggest-selling drug Copaxone

Cipla appoints Novartis’ Subhanu Saxena as CEO

Was previously head of global product strategy and commercialisation at Swiss pharma firm

- PMLiVE

Eliquis cleared in EU for stroke prevention in AF

Follows last year’s approval for the prevention of VTE after surgery for BMS and Pfizer's drug

- PMLiVE

EU approval for AZ/BMS’ first-in-class diabetes drug Forxiga

First SGLT2 inhibitor to be approved for marketing anywhere in the world

german flag

AZ sees Seroquel XR patent overturned in Germany

Follows challenge by Teva, Hexal and Accord Healthcare

- PMLiVE

BMS’ Orencia matches Humira in trial

Head-to-head study shows subcutaneous version as effective as Abbott's drug

Novartis building

Novartis says pipeline is “industry leading”

Touts 14 drug candidates with $1bn-plus sales potential

- PMLiVE

Lundbeck revenues fall on Lexapro competition

Reinforces need for successful vortioxetine launch

- PMLiVE

Teva promotes Allan Oberman to take over from William Marth

Executive leadership changes also see Jill DeSimone join

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links